List
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: Lung Carcinoma, Non-Small-Cell (NSCLC). 18 results shown below.
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Complete title: Personalized Radiation Therapy through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)
Principal Investigator: Jing Zeng
Study Number: 9599
Phase: II
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Complete title: Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies with Defined Subsets of Autologous T cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
Principal Investigator: David Maloney, MD, PhD
Study Number: 9330
Phase: I
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Complete title: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).
Principal Investigator: Christina Baik
Study Number: RG1004973
Phase: II/III
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
Complete title: A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Principal Investigator: Christina Baik
Study Number: RG1006337
Phase: II
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Complete title: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Principal Investigator: Sylvia Lee, MD
Study Number: 10044
Phase: II
Safety Study of SEA-CD40 in Cancer Patients
Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Principal Investigator: Gabriela Chiorean
Study Number: 20152369
Phase: II
A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Complete title: A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS
Principal Investigator: Kit Wong
Study Number: 20171486
Phase: I
Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation
Complete title: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Principal Investigator: Christina Baik
Study Number: 20172584
Phase: II
Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Complete title: A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors
Principal Investigator: Christina Baik
Study Number: 20172740
Phase: I/II
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Complete title: A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Principal Investigator: Nora Disis, MD
Study Number: 20181578
Phase: I
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Complete title: A MULTICENTER, OPEN-LABEL PHASE 1 STUDY
OF U3-1402 IN SUBJECTS WITH METASTATIC OR
UNRESECTABLE EGFR-MUTANT NON-SMALL
CELL LUNG CANCER
Principal Investigator: Christina Baik
Study Number: RG1003503
Phase: I
Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Complete title: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Principal Investigator: Christina Baik
Study Number: RG1003659
Phase: II
A PHASE 2 STUDY TO EVALUATE THE OBJECTIVE RESPONSE TO TARLOXOTINIB ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH NON-SMALL CELL LUNG CANCER THAT HARBORS EITHER EGFR EXON 20 INSERTION OR A HER2-ACTIVATING MUTATION
Principal Investigator: Christina Baik
Study Number: RG1004464
Phase: II
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)
Complete title: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Principal Investigator: Jennifer Specht, MD
Study Number: RG1004763
Phase: I
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)
Complete title: A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced
Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line
Osimertinib Therapy
Principal Investigator: Christina Baik
Study Number: RG1005292
Phase: II
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous NSCLC
Complete title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Principal Investigator: Keith Eaton, MD, PhD
Study Number: RG1005371
Phase: III
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Complete title: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naive EGFR-mutant Locally Advanced or Metastatic NSCLC
Principal Investigator: Christina Baik
Study Number: RG1006640
Phase: II